Evonik Cuts Dividend to Prioritize Financial Flexibility

The German specialty chemicals group Evonik has released its 2025 annual results, accompanied by a fundamental shift in its shareholder remuneration policy. In a move underscoring a focus on financial resilience, the company has reduced its dividend payout from €1.17 to €1.00 per share. This decision comes as Evonik’s share price, currently around €13.96, continues to trade well below its 52-week high of €22.26.

Restructuring Progress Amid Revenue Headwinds

While Evonik met its key operational targets for the year, the broader financial picture reveals significant pressures. The company hit its adjusted EBITDA goal, reporting €1.87 billion. Free cash flow reached €695 million, landing at the upper end of the projected range. Net income also showed improvement, rising to €265 million from €222 million a year earlier.

However, the top-line performance was less favorable. Group revenue declined by 7% to €14.1 billion. This drop was driven by a combination of lower selling prices, weaker sales volumes, and adverse currency effects across both of Evonik’s business segments. Furthermore, the Return on Capital Employed (ROCE) fell to 6.1%, a figure substantially below the company’s medium-term target of 11%.

Price Hike for Key Product to Defend Margins

Concurrent with its annual report, Evonik announced an immediate global net price increase of 10% for its animal feed additive, MetAMINO®. This action is aimed at stabilizing margins within the Advanced Technologies segment. This division generated approximately €5.9 billion in revenue during 2025 but experienced a declining EBITDA margin of 15.8%. The market’s ability to absorb this price increase in a climate of global overcapacity will become clearer when Evonik publishes its first-quarter figures on May 8.

Should investors sell immediately? Or is it worth buying Evonik?

Leadership Vacancy and Revised Outlook

Looking ahead to 2026, Evonik maintains its EBITDA guidance bracket of €1.7 to €2.0 billion. Its revenue forecast, however, has been adjusted downward to a range of €13.5 to €14.5 billion, reflecting expectations of ongoing structural challenges.

The company’s “Evonik Tailor Made” restructuring initiative remains on track for completion by the end of 2026. The program is projected to yield annual savings of around €400 million and will result in the elimination of roughly 2,000 positions, with approximately 1,500 of those in Germany. An additional factor weighing on investor sentiment is the unresolved search for a new Chief Financial Officer (CFO) to fill the vacant post.

The upcoming Annual General Meeting on June 3, 2026, represents a key milestone. Shareholders will vote on the proposed dividend and are expected to discuss the new distribution framework. This revised policy, effective for the 2026 fiscal year, targets a payout ratio of 40% to 60% of adjusted group net income.